These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29463526)

  • 81. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
    Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
    Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
    Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
    [TBL] [Abstract][Full Text] [Related]  

  • 84. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population.
    Ramesh K; Hemanth Kumar AK; Kannan T; Vijayalakshmi R; Sudha V; Manohar Nesakumar S; Bharathiraja T; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1231-5. PubMed ID: 27510251
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The effect of
    Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
    Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
    Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
    Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs.
    Kim SH; Kim SH; Lee JH; Lee BH; Kim YS; Park JS; Jee YK
    Tuberculosis (Edinb); 2012 Jan; 92(1):100-4. PubMed ID: 22178260
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients.
    Vogensen VB; Bolhuis MS; Sturkenboom MGG; van der Werf TS; de Lange WCM; Anthony RM; van Soolingen D; Alffenaar JW; Kerstjens HAM; Akkerman OW
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0182921. PubMed ID: 34807758
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters.
    Annisa N; Barliana MI; Santoso P; Ruslami R
    Front Pharmacol; 2022; 13():1063413. PubMed ID: 36588725
    [TBL] [Abstract][Full Text] [Related]  

  • 92. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
    Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
    Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin.
    Rajput TA; Naveed AK; Farooqi ZR; Khan S
    Pak J Pharm Sci; 2017 Jul; 30(4):1363-1370. PubMed ID: 29039339
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    Xie YL; Chakravorty S; Armstrong DT; Hall SL; Via LE; Song T; Yuan X; Mo X; Zhu H; Xu P; Gao Q; Lee M; Lee J; Smith LE; Chen RY; Joh JS; Cho Y; Liu X; Ruan X; Liang L; Dharan N; Cho SN; Barry CE; Ellner JJ; Dorman SE; Alland D
    N Engl J Med; 2017 Sep; 377(11):1043-1054. PubMed ID: 28902596
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Low rifampicin concentrations in tuberculosis patients with HIV infection.
    Gengiah TN; Botha JH; Soowamber D; Naidoo K; Abdool Karim SS
    J Infect Dev Ctries; 2014 Aug; 8(8):987-93. PubMed ID: 25116663
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
    Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
    Naidoo A; Chirehwa M; Ramsuran V; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ncgapu S; Adamson J; Govender K; Denti P; Padayatchi N
    Pharmacogenomics; 2019 Mar; 20(4):225-240. PubMed ID: 30767706
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine.
    Dohál M; Porvazník I; Solovič I; Mokrý J
    Front Microbiol; 2023; 14():1225438. PubMed ID: 37860132
    [TBL] [Abstract][Full Text] [Related]  

  • 100. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.